Rosuvastatin: Discovery, Development, Safety and Pharmacovigilance

Explains how rosuvastatin moved from a potent synthetic HMG-CoA reductase inhibitor to an extensively used cardiovascular preventive medicine, distinguishing lipid endpoints from clinical outcomes, positive trials from negative heart-failure studies, and jurisdiction-specific safety requirements.

Take test

Rosuvastatin: Discovery, Development, Safety and Pharmacovigilance

Rosuvastatin is a synthetic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. It is a widely used lipid-lowering medicine whose history illustrates a recurring pharmacovigilance challenge: a treatment can have substantial population-level cardiovascular benefit while requiring careful attention to uncommon but serious muscle injury, altered glucose metabolism, renal laboratory findings, and exposure-increasing drug interactions.

This article follows the active substance rosuvastatin, not a single brand or salt presentation. Crestor is the originator brand, but contemporary rosuvastatin is supplied by multiple marketing-authorisation holders. Product information varies by jurisdiction, strength, formulation and revision date. In particular, the United Kingdom Crestor Summary of Product Characteristics (SmPC), updated 9 April 2026, and the United States Crestor prescribing information, revised September 2026, do not have identical contraindications or dose restrictions. Neither should be used as a substitute for the locally authorised text. [1,2]

Discovery: the search for a more potent synthetic statin

The therapeutic idea preceded rosuvastatin. Inhibition of HMG-CoA reductase decreases hepatic cholesterol synthesis, promotes increased hepatocyte low-density lipoprotein (LDL) receptor expression, and accelerates removal of circulating LDL cholesterol. Early statins established the clinical value of this pathway. The medicinal-chemistry challenge was to create compounds with potent, sustained hepatic activity and an acceptable systemic safety profile.

Rosuvastatin was discovered by Shionogi in Japan and investigated under the development designations S-4522 and later ZD4522. A published Australian patent judgment, reproduced by WIPO Lex, documents Shionogi's Phase I work in 1993–1994 and early Phase II work in 1995–1996. It also records Zeneca's April 1998 worldwide development and commercialisation licence, before the creation of AstraZeneca in 1999. This is unusually clear documentary evidence for both the molecule's originating company and its development transfer. [3]

The early dose-finding programme established pronounced reductions in LDL cholesterol at low doses. That pharmacodynamic signal justified larger comparative studies, but early cholesterol lowering could not by itself prove reductions in myocardial infarction, stroke or death. Clinical outcome trials would be required to answer those questions. Likewise, pharmacological potency should not be interpreted as an automatic superiority claim for safety, adherence or clinical benefit in every population.

From Shionogi to AstraZeneca

The 1998 licensing arrangement transferred worldwide development and commercialisation responsibilities to Zeneca, subsequently AstraZeneca, while the originating invention remained Shionogi's. Rosuvastatin entered major markets as Crestor after regulatory evaluation of its lipid-lowering efficacy and safety. The US FDA approved Crestor in August 2003; a contemporaneous drug-development account in Nature Reviews Drug Discovery documents the approval and the early commercial expectations. [3,4]

Later generic availability transformed the product from an originator franchise into a broadly accessible active substance. That change matters for pharmacovigilance: case reports may identify rosuvastatin generically, a particular manufacturer, a brand, or a combination product. Product identity, formulation, dose and batch should be captured when available, particularly when a quality issue or dispensing error is suspected. A change in commercial ownership or generic competition does not change the molecular mechanism, but it changes the operational network responsible for case collection, signal exchange and product-specific labelling.

Mechanism, pharmacokinetics and exposure

Rosuvastatin competitively inhibits HMG-CoA reductase. Reduced intracellular cholesterol in hepatocytes increases LDL receptor-mediated clearance of LDL particles and lowers circulating LDL cholesterol, apolipoprotein B and non-HDL cholesterol. Its pharmacological target is the liver, although systemic exposure is relevant to adverse reactions. Rosuvastatin is not a prodrug and is not dependent on extensive CYP3A4 metabolism for activation. [1,2]

The drug has an elimination half-life of approximately 19 hours, allowing once-daily dosing. It undergoes relatively limited metabolism; hepatic uptake and efflux transporters are important determinants of disposition. In particular, OATP1B1 (encoded by SLCO1B1) and BCRP (encoded by ABCG2) influence exposure. Certain transporter variants and inhibitors can increase plasma concentrations and alter the benefit–risk balance. The UK SmPC specifically discusses higher exposure associated with some SLCO1B1 and ABCG2 genotypes. [1]

The practical implication is more precise than calling rosuvastatin a statin with “few interactions.” A drug can have limited CYP metabolism yet still interact substantially through transporters. Co-prescribed agents such as ciclosporin, some antivirals and newer targeted treatments may markedly increase rosuvastatin exposure. The appropriate response depends on the actual combination and regional label, not on a generic assumption that all statins share the same interaction rules.

Early development and the importance of endpoints

Phase I studies characterised tolerability and pharmacokinetics, while dose-ranging and comparative studies established LDL lowering. The STELLAR programme compared rosuvastatin with several other statins at specified doses, supporting the assessment of lipid efficacy. Such studies answered how much a lipid measure changed, not whether one agent would prevent more clinical events over decades.

Later imaging studies, including ASTEROID and SATURN, investigated coronary atherosclerosis burden. ASTEROID evaluated rosuvastatin 40 mg without a concurrent control group; 349 participants had interpretable baseline and follow-up intravascular ultrasound images after two years. SATURN compared intensive rosuvastatin and atorvastatin regimens. Plaque measures are biologically informative but are not identical to mortality or major cardiovascular-event outcomes. The trial programme therefore spans a hierarchy of evidence: pharmacodynamic biomarkers, anatomical surrogates and clinical events. [5,13]

That distinction is essential for interpretation. A large LDL reduction supports biological activity and often predicts vascular benefit at a population level, but the observed effect on a particular clinical outcome must be attributed to the actual trial population, regimen, duration and endpoint.

Pivotal clinical evidence: what was demonstrated?

JUPITER: first cardiovascular events in a selected primary-prevention population

The JUPITER trial enrolled 17,802 apparently healthy men aged at least 50 years and women aged at least 60 years who had LDL cholesterol below 130 mg/dL but high-sensitivity C-reactive protein at least 2 mg/L. Participants received rosuvastatin 20 mg daily or placebo. The prespecified composite cardiovascular endpoint occurred at rates of 0.77 versus 1.36 events per 100 person-years, respectively; the reported hazard ratio was 0.56 (95% CI 0.46–0.69). The trial was stopped early after a median follow-up of about 1.9 years following an independent monitoring recommendation. [6]

The result was important because it demonstrated an outcome benefit beyond treating only markedly elevated baseline LDL cholesterol. However, the inclusion criteria limit direct extrapolation to all low-risk adults, younger populations or people without the trial's inflammatory-marker profile. Early termination also limits the precision with which longer-term treatment effects and uncommon adverse events can be assessed.

JUPITER also reported a higher frequency of physician-reported diabetes in the rosuvastatin group. The UK Crestor SmPC describes 2.8% versus 2.3% in rosuvastatin and placebo recipients, mainly among participants with baseline fasting glucose in a prediabetic range. This finding illustrates why a favourable cardiovascular endpoint does not imply an absence of treatment-emergent metabolic harms. The net benefit depends on baseline cardiovascular risk and the magnitude of potential benefit. [1,6]

HOPE-3: a broader intermediate-risk population

The HOPE-3 trial evaluated rosuvastatin 10 mg daily in people at intermediate cardiovascular risk without established cardiovascular disease. Its international, ethnically diverse population and approximately 5.6 years of treatment offered evidence beyond the narrower JUPITER inclusion criteria. Rosuvastatin reduced the risk of the trial's composite cardiovascular outcomes compared with placebo. The result supported preventive use based on overall risk rather than treating a laboratory threshold in isolation. [7]

The two trials should not be collapsed into a single estimate: they used different entry criteria, doses, follow-up periods and outcome definitions. Absolute benefit also depends on underlying event rates. For clinical decisions, the relevant comparator is not merely the relative hazard ratio but the expected absolute reduction in events against adverse effects, treatment burden and patient preferences.

Negative or non-confirmatory evidence: CORONA and GISSI-HF

An effective LDL-lowering treatment does not necessarily improve outcomes in every advanced cardiovascular syndrome. In CORONA, rosuvastatin was studied in older patients with systolic heart failure of ischaemic origin; the primary composite cardiovascular outcome was not significantly reduced. In GISSI-HF, 4,574 patients with chronic heart failure were randomised to rosuvastatin 10 mg daily or placebo. After a median 3.9 years, all-cause mortality was 29% versus 28%, with an adjusted hazard ratio of approximately 1.00, and the co-primary death-or-cardiovascular-hospitalisation outcome was also not improved. [8,9]

These are not evidence that rosuvastatin never benefits patients who happen to have heart failure and a separate lipid-lowering indication. They show that prescribing rosuvastatin specifically to treat established symptomatic heart failure was not supported by these trials. This distinction prevents an efficacy claim from being expanded beyond the evidence.

Imaging and lipid studies: supportive but not substitutes

STELLAR demonstrated substantial LDL lowering across compared statin regimens; ASTEROID and SATURN assessed atheroma-related surrogate outcomes. SATURN compared rosuvastatin 40 mg with atorvastatin 80 mg in patients with coronary disease. Neither a surrogate improvement nor a head-to-head lipid difference should be represented as a demonstrated reduction in mortality unless an appropriately designed outcomes study supports it. [5]

Evidence programme Main question What it can establish Important limit
Early dose-ranging and STELLAR How strongly does LDL cholesterol fall? Dose response and comparative lipid effects Lipid changes are not clinical-event counts
ASTEROID and SATURN Does coronary atheroma change? Imaging response under intensive treatment Plaque imaging is a surrogate
JUPITER Are first major events reduced in a selected elevated-hsCRP population? Randomised cardiovascular benefit Early stopping; selected population
HOPE-3 Is there benefit in intermediate-risk primary prevention? Randomised outcomes in a broader population Different dose and risk distribution from JUPITER
CORONA and GISSI-HF Does rosuvastatin improve established heart-failure outcomes? No significant improvement in specified primary outcomes Does not negate other lipid-lowering indications

Regulatory and formulation lifecycle

Rosuvastatin first entered major markets for hypercholesterolaemia and related lipid disorders; subsequent clinical evidence supported prevention of major cardiovascular events in appropriate at-risk populations. Contemporary UK Crestor labelling includes treatment of primary and familial hypercholesterolaemia and prevention of major cardiovascular events in people at high risk of a first event, as an adjunct to managing other risk factors. It also includes specified paediatric populations, with specialist-directed dose ranges. [1]

The September 2026 US label contains its own indication, paediatric, dosing and interaction provisions. Neither UK authorisation nor US approval is a single universal global licence. Rosuvastatin is marketed by numerous holders and in different strengths and formulations, and the authorised text should be checked for the actual product. [1,2]

The licensing history and later generic competition created a mature market with multiple finished products. Safety evaluation must therefore distinguish active-substance signals from manufacturer-specific defects, changes in excipients, dose-form confusion, fixed combinations and medication errors. A case report that says only “statin” or “cholesterol pill” requires follow-up for the exact product.

Why clinical success increases the importance of safety surveillance

Rosuvastatin is often taken for years by patients who may have few or no symptoms before treatment. This changes the practical safety equation: even rare serious reactions matter when exposure is large and prolonged, and nonspecific symptoms such as muscle pain may arise for reasons unrelated to treatment. The role of pharmacovigilance is to distinguish plausible adverse reactions and preventable exposure problems from background disease and coincidence without discounting either the medicine's proven benefit or patients' reported symptoms.

Skeletal muscle toxicity: a spectrum, not one diagnosis

Myalgia, clinically significant myopathy and rhabdomyolysis differ in severity, objective findings and implications. A patient may report muscle pain with normal creatine kinase (CK), whereas rhabdomyolysis involves substantial muscle breakdown and may cause acute kidney injury. The current UK Crestor SmPC describes a higher reporting rate of rhabdomyolysis at 40 mg than at lower doses; this does not establish an exact population incidence from spontaneous reports. Risk is modified by dose, interacting medicines, renal impairment, untreated hypothyroidism and other predisposing conditions. [1,2]

A useful initial case assessment reconstructs the symptom pattern, proximal versus focal distribution, exercise, trauma, infection, thyroid function, renal function, CK values, urine findings, treatment dose and start date, co-medications, and whether symptoms improved after interruption. CK should be interpreted against the clinical situation: recent vigorous exercise and other causes can confound the result. Severe symptoms can justify urgent medical assessment even before a complete laboratory work-up.

Immune-mediated necrotising myopathy is different

Rare immune-mediated necrotising myopathy (IMNM) associated with statins can produce persistent proximal weakness and markedly elevated CK despite discontinuation. Anti-HMGCR antibodies, specialist investigations and, where appropriate, biopsy can help distinguish it from self-limited toxic myopathy. The September 2026 US label notes possible recurrence after the same or a different statin and that immunosuppressive treatment may be necessary. [2]

This difference has immediate pharmacovigilance consequences. A simple “muscle symptoms resolved on stopping” narrative is not an adequate template for every case. Persistence after withdrawal, autoimmune investigation and treatment course should be documented; re-exposure to another statin may be clinically important and should not be recommended mechanically.

Other neuromuscular signals

Current UK labelling describes reports of new or aggravated myasthenia gravis, including ocular myasthenia, and recurrence after re-exposure to statins. Case review should distinguish fatigue from objective fluctuating weakness, ocular symptoms and established neuromuscular disease. The existence of a labelled warning does not make every report causally proven. [1]

Liver, renal and metabolic safety

Hepatic injury

Transient aminotransferase increases are described in clinical studies; rare severe hepatic outcomes are reported after marketing. The US label recommends considering liver enzyme testing before treatment and when clinically indicated, and prompt discontinuation when serious hepatic injury with symptoms or hyperbilirubinaemia occurs. The UK Crestor SmPC recommends liver function tests before treatment and three months after initiation, and sets specific action guidance for transaminase elevations. These are jurisdiction-specific instructions, not interchangeable global rules. [1,2]

For a suspected liver injury case, capture baseline and serial ALT, AST, alkaline phosphatase, bilirubin, international normalised ratio where relevant, symptoms, alcohol exposure, viral hepatitis, other hepatotoxic medicines, and dechallenge. Differentiate isolated biochemical abnormalities from clinically apparent drug-induced liver injury. Causality assessment should consider competing disease and exposure timing rather than relying solely on a temporal association.

Proteinuria, haematuria and kidney injury

Proteinuria detected by dipstick, often tubular in character, and microscopic haematuria have been observed, especially at higher rosuvastatin doses. The US label says these findings were generally transient and not associated with worsening renal function in the clinical programme; it advises considering dose reduction for unexplained persistent proteinuria or haematuria. The UK SmPC similarly states that the observed proteinuria has not been shown to predict acute or progressive renal disease, while noting higher reporting of serious renal events at 40 mg. [1,2]

A pharmacovigilance assessment must distinguish a laboratory finding from acute kidney injury, chronic kidney disease, nephrotic disease and renal injury secondary to rhabdomyolysis. Obtain serum creatinine trends, estimated renal function, urinalysis type, urine protein quantification if available, CK, blood pressure and concomitant nephrotoxic medicines. Do not automatically classify transient isolated proteinuria as confirmed drug-induced kidney failure.

Glycaemic effects

Statins, including rosuvastatin, can increase fasting glucose and HbA1c and may accelerate recognition of diabetes in susceptible individuals. JUPITER's difference in physician-reported diabetes provides a trial-based signal, but risk should be interpreted alongside the cardiovascular events prevented. The UK SmPC explicitly describes the cardiovascular benefit as outweighing the class-associated glycaemic risk in appropriate patients. [1,6]

A report of new diabetes should include baseline glucose, HbA1c, body mass index, family history, concurrent corticosteroids or other diabetogenic drugs, and the interval from treatment initiation. An association seen in randomised trials does not establish that every individual case of diabetes was caused by rosuvastatin.

Serious skin and other post-marketing reactions

UK labelling describes severe cutaneous adverse reactions including Stevens–Johnson syndrome and DRESS. The US post-marketing section also includes uncommon neurological and haematological reports. For suspected severe skin reactions, document rash morphology, mucosal involvement, fever, eosinophilia, organ involvement, time to onset and all recently started medicines. These are medically urgent events; routine nonspecific rash should not be equated with a severe cutaneous adverse reaction. [1,2]

Drug interactions: transporter inhibition is central

Because rosuvastatin depends on transporters such as OATP1B1 and BCRP, drugs that inhibit those pathways can increase systemic exposure. This is why it is unsafe to infer rosuvastatin interaction management from CYP3A4 rules alone. The UK and US labels also differ in how certain interactions are managed. [1,2]

Clinical situation September 2026 US Crestor label April 2026 UK Crestor SmPC PV implication
Ciclosporin/cyclosporine Rosuvastatin maximum 5 mg daily Contraindicated concomitant use Record country and actual authorisation; do not import a US allowance into UK practice
Severe renal impairment Reduced starting and maximum doses specified Contraindicated at all doses when creatinine clearance <30 mL/min Check renal function and label-specific eligibility
Asian ancestry Start at 5 mg, with individualised assessment Start at 5 mg; 40 mg contraindicated Exposure risk varies; avoid stereotyping individuals or inventing genotype
Gemfibrozil Avoid if possible; if unavoidable, start 5 mg and do not exceed 10 mg Combination not recommended; 40 mg contraindicated with fibrates Assess both transporter/pharmacodynamic myopathy risk
Selected antivirals and targeted therapies Drug-specific dose limits or avoidance Interaction-specific restrictions; some combinations contraindicated Identify the exact agent, not just the therapeutic class

This table is a comparison of two particular product labels, not a prescribing algorithm. For example, the UK SmPC contraindicates concomitant sofosbuvir/velpatasvir/voxilaprevir, while the US label supplies detailed antiviral interaction provisions. Regulatory decisions and dosing instructions must always be checked against the current locally authorised product. [1,2]

Warfarin is a different kind of interaction: changes in rosuvastatin treatment can alter INR, requiring appropriate monitoring under the applicable label. Aluminium/magnesium antacids can reduce rosuvastatin exposure if given simultaneously; the US label directs giving Crestor at least two hours before such an antacid. These interactions may present as abnormal anticoagulation or reduced lipid response rather than myopathy. [2]

The September 2026 US label includes specific restrictions involving newer medicines such as tafamidis, belumosudil and vadadustat. The clinically relevant lesson is not to memorise a static list: maintain a current interaction-screening process and document the product information version used when reviewing a serious event. [2]

Regional safety differences and special populations

Pregnancy and lactation: a change in US regulatory reasoning

The FDA's 20 July 2021 statin safety communication requested removal of the blanket pregnancy contraindication because some exceptionally high-risk pregnant patients may have an individualised benefit–risk case for treatment. It continued to advise that most pregnant patients discontinue statins, and that breastfeeding is not recommended during treatment. The September 2026 US Crestor label reflects this nuanced approach. It is inaccurate to say that the FDA declared statins generally safe or routinely indicated in pregnancy. [2,10]

UK Crestor product information uses a different regulatory formulation and must be followed in that jurisdiction. A PV report of gestational exposure should include maternal cardiovascular diagnosis, exact gestational timing, dose, interruption, concomitant medicines, pregnancy outcome and infant follow-up where available. Exposure alone is not evidence of fetal harm, and observational evidence must be interpreted with maternal comorbidity and confounding in mind.

Renal impairment, ancestry and pharmacogenetics

Renal function can alter dosing eligibility and safety. UK Crestor labelling contraindicates all doses in severe renal impairment, whereas the US label specifies reduced doses in that situation. Increased average exposure in some Asian populations has informed labelled starting-dose advice, but ancestry is an imperfect proxy for individual transporter genotype, renal function and other risk factors. A careful review uses the actual patient information and applicable regional label without inferring genotype from ethnicity. [1,2]

Paediatric use and the EU regulatory history

Crestor was first authorised in the EU in the Netherlands in November 2002. EMA documents a 2014 Article 29 paediatrics referral concerning Crestor and associated names, with a European Commission decision on 30 June 2014. This illustrates how a nationally authorised product can undergo EU-level referral procedures without being a centrally authorised EMA EPAR product. [11]

The UK Crestor SmPC describes specific paediatric familial-hypercholesterolaemia indications and age-dependent dose ranges. Children are not simply small adults: growth and maturation observations, CK increases associated with activity, administration, and long-term cumulative exposure warrant appropriately designed surveillance. [1]

From an adverse-event report to a medically useful case

A high-quality rosuvastatin case record starts with the exact medicinal product, manufacturer where known, daily dose, formulation, treatment dates, indication and country. It then reconstructs the clinical course with sufficient detail to distinguish expected symptoms, medically important toxicity and plausible alternatives.

Consider an illustrative, not real, case: a patient stable on rosuvastatin 20 mg develops progressive proximal weakness after starting a transporter-inhibiting medicine. CK is markedly elevated and renal function deteriorates. The assessor should obtain the new medicine's identity, initiation date, renal and thyroid history, exercise and infection history, serial CK and creatinine, drug interruption dates, and subsequent clinical course. The interaction may provide a biologically plausible explanation, but neither the interaction nor the timing eliminates other causes. If weakness and CK elevation persist after withdrawal, specialist evaluation for IMNM becomes particularly important.

A second illustrative case involves persistent microscopic haematuria on 40 mg rosuvastatin. Without renal function trends, urinary protein assessment, infection history and alternative urological causes, the report cannot distinguish a labelled laboratory finding from unrelated renal pathology. Good case processing preserves that uncertainty rather than upgrading every laboratory result to severe kidney injury.

Case-follow-up priorities by phenotype

Reported problem High-value follow-up Common interpretation error
Muscle pain or weakness CK trajectory, functional impact, interacting drugs, renal and thyroid status, dechallenge Calling every myalgia rhabdomyolysis
Persistent weakness after stopping Proximal strength, CK, anti-HMGCR work-up, specialist diagnosis Assuming all statin myopathy resolves immediately
Elevated liver tests ALT/AST/ALP/bilirubin sequence, symptoms, other causes, interruption Equating isolated transaminase elevation with liver failure
Proteinuria or haematuria Urine results, creatinine, CK, baseline kidney disease, persistence Treating every dipstick finding as progressive renal disease
New diabetes Baseline HbA1c/glucose, metabolic risk, concurrent medicines Ignoring background diabetes risk and trial-level absolute effects
Pregnancy exposure Gestational dates, indication, dose, maternal and infant outcomes Assuming exposure proves fetal injury

Pharmacovigilance governance and inspection perspective

In the EU, a marketing-authorisation holder's PV system should collect and evaluate suspected adverse reactions, assess signals, maintain current product information and take proportionate regulatory action. EMA GVP provides guidance for ICSR management, signal management, aggregate evaluation and risk minimisation; it does not make a single UK SmPC a binding instruction for every EU Member State. [12]

For rosuvastatin, useful governance questions include whether interaction knowledge is updated when new co-medications enter practice; whether myopathy and IMNM are distinguished in medical review; whether higher-dose renal findings are evaluated without inflated severity; and whether the safety database retains product, dose, renal function and co-medication detail. Generic products and combination presentations complicate traceability and duplicate detection. These are recommended review questions, not assertions of actual inspection findings.

A signal team should triangulate spontaneous cases, clinical-trial evidence, observational studies, literature, exposure estimates and the known class profile. Reporting rates cannot be converted directly into incidence. A cluster of reports after an interaction-label revision may reflect stimulated reporting rather than a true change in underlying risk; conversely, a plausible serious case warrants review even if the absolute report count is low. The evidence-to-action trail should show who assessed the signal, what alternative explanations were considered, and why the resulting decision was proportionate.

Practical checklist and key takeaways

Before interpreting a suspected rosuvastatin adverse reaction, verify the actual product and regional label, dose and recent changes, clinical indication, baseline cardiovascular risk, kidney and liver function, co-medications, relevant symptoms and objective findings. For a severe reaction, obtain time-resolved laboratory and clinical data and identify urgent follow-up needs. Record whether the evidence supports a suspected reaction, an interaction, a product-quality concern or an alternative diagnosis, without forcing certainty.

Rosuvastatin's lifecycle connects Japanese medicinal chemistry and international licensing with major preventive cardiovascular trials, informative negative heart-failure studies and evolving safety labelling. Its most consequential PV distinctions are ordinary muscle symptoms versus serious toxic or immune-mediated disease, transient renal findings versus genuine kidney injury, transporter-mediated exposure versus assumptions based on CYP metabolism, and US versus UK/EU legal labelling. The clinical value of statin treatment and the obligation to investigate serious suspected harm are complementary, not competing, responsibilities.

References

  1. AstraZeneca UK Limited. Crestor 10 mg film-coated tablets: Summary of Product Characteristics. Electronic Medicines Compendium; updated 9 April 2026. https://www.medicines.org.uk/emc/product/7559/smpc
  2. US National Library of Medicine / FDA Structured Product Label. Crestor (rosuvastatin calcium) prescribing information. DailyMed; revised September 2026. https://dailymed-beta.nlm.nih.gov/dailymed/drugInfo.cfm?setid=325a5d0e-9a72-4015-9fcd-1655fb504cee
  3. Australian Federal Court. Rosuvastatin patent and inventorship judgment, reproduced by WIPO Lex; documentary history of Shionogi S-4522 and the 1998 Zeneca licence. https://www.wipo.int/wipolex/en/text/579041
  4. Quirk J, Thornton M, Kirkpatrick P. Rosuvastatin calcium. Nature Reviews Drug Discovery. 2003;2:769–770. https://www.nature.com/articles/nrd1205
  5. Nicholls SJ, et al. Effect of two intensive statin regimens on progression of coronary disease (SATURN). N Engl J Med. 2011;365:2078–2087. https://doi.org/10.1056/NEJMoa1110874
  6. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359:2195–2207. https://doi.org/10.1056/NEJMoa0807646
  7. Yusuf S, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease (HOPE-3). N Engl J Med. 2016;374:2021–2031. https://doi.org/10.1056/NEJMoa1600176
  8. Kjekshus J, et al. Rosuvastatin in older patients with systolic heart failure (CORONA). N Engl J Med. 2007;357:2248–2261. https://doi.org/10.1056/NEJMoa0706201
  9. Tavazzi L, et al. Effect of rosuvastatin in patients with chronic heart failure (GISSI-HF). Lancet. 2008;372:1231–1239. https://doi.org/10.1016/S0140-6736(08)61240-4
  10. US Food and Drug Administration. FDA requests removal of strongest warning against statin use during pregnancy. Drug Safety Communication; 20 July 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy
  11. European Medicines Agency. Crestor and associated names: Article 29 paediatrics referral. European Commission decision 30 June 2014. https://www.ema.europa.eu/en/medicines/human/referrals/crestor-associated-names
  12. European Medicines Agency. Good pharmacovigilance practices (GVP), current module collection. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
  13. Nissen SE, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: ASTEROID. JAMA. 2006;295:1556–1565. https://doi.org/10.1001/jama.295.13.jpc60002

Regulatory Note

This is a scientific and pharmacovigilance reference, not individual prescribing advice. The UK Crestor SmPC (9 April 2026), US Crestor label (September 2026), historical EMA referral and scientific trials serve different purposes. UK product information is not automatically EU-wide binding text, and the FDA label is not a substitute for national EU authorisations. Clinical decisions and regulatory obligations require the current locally authorised product information and applicable legislation. Hypothetical cases and operational recommendations are identified as such; no invented inspection findings, incidence estimates or universal monitoring requirements are asserted.

Revision History

Last reviewed: 2026-10-22

QPPV.com